562 results on '"Kumthekar, Priya"'
Search Results
202. ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE
203. NIMG-21. SEX DIFFERENCES IN EXTREME SURVIVORSHIP AMONG PRIMARY GLIOBLASTOMA PATIENTS
204. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
205. Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis
206. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients withEGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
207. Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study
208. Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade.
209. A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).
210. Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
211. Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
212. Chapter 47 - Neuroimaging of Glioneuronal Tumors
213. Atypical meningioma: Randomized trials are required to resolve contradictory retrospective results regarding the role of adjuvant radiotherapy
214. Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma
215. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation
216. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
217. HOUT-27. TREATMENT PATTERNS AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE DATABASE ANALYSIS USING US ELECTRONIC HEALTH RECORDS (EHR)
218. ATIM-10. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM
219. ACTR-88. A PHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS
220. ACTR-19. A PHASE 2 STUDY OF TUMOR TREATING FIELDS AND BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA
221. CMET-44. HER2 AND TRIPLE NEGATIVE BREAST CANCER PATIENTS DEMONSTRATE AN EARLIER TIME TO DEVELOPMENT OF BRAIN METASTASES
222. PATH-29. MOLECULAR DETERMINANTS ASSOCIATED WITH RESPONSE AND RESISTANCE TO DEPATUXIZUMAB MAFODOTIN (ABT-414) IN PATIENTS WITH RECURRENT GLIOBLASTOMA
223. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
224. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma
225. Gene Delivery in Neuro-Oncology
226. State-of-the-art considerations in small cell lung cancer brain metastases
227. A pilot study of palbociclib in patients with HER2-positive breast cancer with brain metastasis.
228. Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.
229. Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC).
230. Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.
231. Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.
232. A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas
233. A case of neuronal gigantism and cortical thickening: A rare complication of therapeutic radiation (P6.187)
234. Mutant IDH1 and seizures in patients with glioma
235. Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases.
236. Quality of Life of Family Caregivers of Patients With Cancer in Korçe, Albania.
237. Mutant IDH1 and seizures in patients with glioma.
238. ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA
239. Prognosis of older patients with low-grade glioma: A retrospective study
240. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
241. ACTR-07. EFFICACY OF A NOVEL ANTIBODY-DRUG CONJUGATE (ADC), ABT-414, AS MONOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (EGFRamp), RECURRENT GLIOBLASTOMA (rGBM)
242. TMOD-08. PDX MODELING OF RECURRENT GLIOBLASTOMA FOR TESTING SALVAGE THERAPIES
243. BMET-28. THE NOVEL BRAIN PENETRATING PEPTIDE-DRUG CONJUGATE ANG1005 SHOWS ACTIVITY IN LC SUBSET OF PATIENTS WITH RECURRENT CNS METASTASIS FROM BREAST CANCER
244. TMOD-26. DEVELOPING PATIENT-DERIVED XENOGRAFT MODELS OF METASTATIC CANCER TO THE BRAIN
245. ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
246. NCOG-02. PREDICTORS OF SEIZURE IN GLIOMA AT INITIAL TUMOR PRESENTATION
247. Mutant IDH1 and thrombosis in gliomas
248. Improving vaccine efficacy against malignant glioma
249. ANG1005, a novel brain-penetrant taxane derivative, for the treatment of recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.
250. Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.